01 Development of Antibiotic–Beta-Lactamase Inhibitor Combinations The antibiotic-resistant infections treatment market analysis highlights the increasing development of antibiotic combinations to overcome bacterial resistance mechanisms. Pharmaceutical companies are focusing on beta-lactamase inhibitors that restore antibiotic effectiveness against resistant Gram-negative bacteria. These combinations are expanding treatment options for difficult-to-treat infections. For example, AbbVie's Emblaveo (aztreonam-avibactam) combines an antibiotic with a beta-lactamase inhibitor to treat certain resistant bacterial infections.
02 Focus on Oral Antibiotics for Resistant Urinary Tract Infections Pharmaceutical companies are developing oral antibacterial formulations targeting pathogens with reduced susceptibility to commonly prescribed drugs. These treatments can provide alternatives to injectable therapies for eligible patients. Orlynvah, an oral penem-based combination, demonstrated improved treatment responses against ciprofloxacin-resistant pathogens in clinical trials.
01 Supply chain disruptions are expected to have a moderate impact on the antibiotic-resistant infections treatment market share due to shortages of active pharmaceutical ingredients, limited antibiotic manufacturing capacity, and dependence on specialized suppliers. The market is expected to experience a K-shaped recovery, with established pharmaceutical companies recovering faster than smaller antibiotic developers. The market is projected to grow at a CAGR of 5.30%. Supply constraints could temporarily reduce growth by an illustrative 1.5 percentage points to approximately 3.80%. Improved antibiotic production capacity, stable raw material supplies, and better hospital procurement systems are expected to support recovery toward the projected 5.30% growth rate.
01 The antibiotic-resistant infections treatment market forecasts continued investment in novel antibiotic development and alternative antibacterial therapies.
02 Key Investment and Funding Activities in Antibiotic-Resistant Infections Treatment Market, 2025–2026 Company Value (USD Details Armata Pharmaceuticals USD 3.7 Million In September 2026, Armata received additional US government funding to support development of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bloodstream infections. Centauri Therapeutics USD 5.1 Million In July 2025, Centauri received additional CARB-X funding to advance its ABX-01 antimicrobial candidate toward clinical trials. ArrePath USD 3.7 Million In April 2025, CARB-X awarded funding to advance a novel antibiotic targeting multidrug-resistant Enterobacterales responsible for complicated urinary tract infections.
01 Need for Resistance Mechanism-Specific Antibiotic Therapies and Oral Treatment Alternatives to Intravenous Antibiotics Drives Market The growing identification of specific bacterial resistance mechanisms is strengthening demand for targeted antibacterial treatments. Hospitals require specialized antibiotics for infections caused by carbapenemase-producing Enterobacterales, particularly NDM-producing strains. According to the Infectious Diseases Society of America, aztreonam-avibactam and cefiderocol are preferred treatment options for NDM-producing Enterobacterales infections. This clinical preference is supporting demand for specialized antibiotic combinations that remain effective against specific resistance mechanisms.Need to reduce dependence on intravenous antibiotics is strengthening demand for effective oral treatments against resistant infections. Hospitals are seeking oral alternatives that support outpatient treatment and reduce hospitalization requirements. For example, Iterum Therapeutics' Orlynvah (sulopenem etzadroxil and probenecid) provides an oral treatment option for adult women with uncomplicated urinary tract infections who have limited or no alternative oral antibiotics. This unmet treatment need supports market growth.
01 Strict Antibiotic Stewardship Policies and Limited Availability of Innovative Antibiotic Candidates Restrain Market Expansion Hospital antibiotic stewardship programs restrict the unnecessary use of advanced antibiotics to preserve their effectiveness. Reserve antibiotics are generally prescribed when standard treatments are unsuitable or ineffective. These restrictions limit prescription volumes even when effective therapies are available. Consequently, pharmaceutical companies face lower commercial returns from newly developed antibiotics. Shortage of antibiotics with new mechanisms of action is limiting treatment options for highly resistant bacterial infections. Existing antibiotic classes often face cross-resistance, reducing their effectiveness against priority pathogens. Pharmaceutical developers also face difficulties demonstrating clinical benefits against resistant infections. These limitations restrict the introduction of differentiated treatments and increase dependence on existing antibiotics.
01 Development of Personalized Bacteriophage Therapy and Adoption of Rapid Antibiotic Susceptibility Testing Creates Treatment Opportunities Development of personalized bacteriophage therapies is creating growth opportunities for biotechnology companies to address infections resistant to conventional antibiotics. These therapies use bacteria-specific viruses to target resistant pathogens without relying on traditional antibiotic mechanisms. Advances in phage susceptibility testing support the selection of suitable treatments for individual patients. Engineered bacteriophages offer potential treatment options against multidrug-resistant Pseudomonas aeruginosa and Staphylococcus aureus, supporting future market expansion.Advanced molecular diagnostics and automated phenotypic testing help clinicians identify effective antibiotics in less time. These technologies support appropriate treatment selection and reduce unnecessary antibiotic use. Pharmaceutical companies can develop diagnostic-guided antibacterial therapies, particularly for carbapenem-resistant Gram-negative infections, supporting more precise treatment approaches and market expansion.